ResearchPod Summary
Despite long-term antiretroviral therapy (ART), HIV-1 persists in a reservoir of infected CD4+ T cells. While these cells are known to be long-lived, the mechanisms allowing them to survive host immune surveillance remain poorly understood. This study investigates whether specific phenotypic profiles characterize these reservoir cells and if these profiles contribute to their persistence.
The researchers developed a single-cell proteogenomic profiling technique called 'phenotypic and proviral sequencing' (PheP-seq). This method allows for the simultaneous analysis of surface protein expression and the integrity of HIV-1 proviral DNA in individual memory CD4+ T cells. By analyzing over one million cells from the peripheral blood and lymph nodes of individuals on long-term ART, the team compared the phenotypes of cells harboring intact proviruses, defective proviruses, and uninfected cells.
The study reveals that HIV-1 reservoir cells are not phenotypically uniform. Cells harboring intact, potentially replication-competent proviruses display distinct signatures that differ by anatomical location. In peripheral blood, these cells frequently express immune checkpoint markers (such as PD1 and TIGIT) and ligands that inhibit cytotoxic T and natural killer cell activity (such as HVEM and PVR). In lymph nodes, the reservoir cells are characterized by the upregulation of survival-promoting markers, including CD44, CD28, and the IL-21 receptor. These findings suggest that the reservoir is shaped by active immune selection, where only cells with optimal adaptations to their specific tissue microenvironment survive.
Understanding the phenotypic adaptations of the HIV-1 reservoir provides critical insights into why current treatments fail to eradicate the virus. The identification of these survival-associated markers suggests that the reservoir is not merely a passive collection of infected cells, but a dynamic population shaped by host immune pressure. These findings may inform future therapeutic strategies, such as those aiming to accelerate the immune-mediated clearance of these adapted reservoir cells to achieve a functional cure.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.